XRCC1 Gene Polymorphism, Clinicopathological Characteristics and Stomach Cancer Survival in Thailand

  • Published : 2015.09.02


Background: Stomach cancer is one of leading causes of death worldwide. In Thailand, the incidence and mortality of stomach cancer are in the top ten for cancers. Effects of DNA repair gene X-ray repair cross complementary protein 1 (XRCC1) polymorphisms and clinicopathological characteristics on survival of stomach cancer in Thailand have not been previously reported. The aim of this study was to investigate the effects of XRCC1 gene and clinicopathological characteristics on survival of stomach cancer patients in Thailand. Materials and Methods: Data and blood samples were collected from 101 newly diagnosed stomach cancer cases pathologically confirmed and recruited during 2002 to 2006 and followed-up for vital status until 31 October 2012. Genotype analysis was performed using real-time PCR-HRM. The data were analyzed using the Kaplan-Meier method to yield cumulative survival curve, log-rank test to assess statistical difference of survival and Cox proportional hazard models to estimate adjusted hazard ratio. Results: The total followed-up times were 2,070 person-months, and the mortality rate was 4.3 per 100 person-months. The median survival time after diagnosis was 8.07 months. The cumulative 1-, 3-, 5-years survival rates were 40.4%, 15.2 % and 10.1 % respectively. After adjustment, tumour stage were associated with an increased risk of death (p= 0.036). The XRCC1 Gln339Arg, Arg/Arg homozygote was also associated with increased risk but statistically this was non-significant. Conclusions: In addition to tumour stage, which is an important prognostic factor affecting to the survival of stomach cancer patients, the genetic variant Gln339Arg in XRCC1 may non-significantly contribute to risk of stomach cancer death among Thai people. Larger studies with different populations are need to verify ours findings.


  1. Wang S, Wu X, Chen Y, et al (2012). Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clinical Cancer Research, 18, 2987-96.
  2. Xu J, Ma J, Zong HT, et al (2014). Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: A systematic review and meta-analysis. Genetics and Molecular Research, 13, 1438-46.
  3. Yi L, Xiao -Feng H, Yun-Tao L, et al (2013). Association between the XRCC1 Arg399Gln polymorphism and risk of cancer: evidence from 297 case-control studies. PloS One, 8, 78071.
  4. Yin C, Li D, Sun Z, et al (2012). Clinicopathologic features and prognosis analysis of mucinous gastric carcinoma. Medical Oncology, 29, 864-70.
  5. Yuan T, Deng S, Chen M, et al (2011). Association of DNA repair gene XRCC1 and XPD polymorphisms with genetic susceptibility to gastric cancer in a Chinese population. Cancer Epidemiology, 35, 170-4.
  6. Zhang X, Jiang LP, Yin Y, Wang YD. (2014). XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 35, 5637-45.
  7. Zou HZ, Yang SJ (2012). Prediction role of seven SNPs of DNA repair genes for survival of gastric cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 6187-90.
  8. Liu B, Wei J, Zou Z, et al (2007). Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. European Journal of Human Genetics, 15, 1049-53.
  9. Okholm C, Svendsen LB, Achiam MP (2014). Status and prognosis of lymph node metastasis in patients with cardia cancer - a systematic review. Surgical Oncology, 23, 140-6.
  10. Pan XF, Xie Y, Loh M, et al (2012). Polymorphisms of XRCC1 and ADPRT genes and risk of noncardia gastric cancer in a Chinese population: A casecontrol study. Asian Pac J Cancer Prev, 13, 5637-42.
  11. Posteraro B, Persiani R, Dall’Armi V, et al (2014). Prognostic factors and outcomes in Italian patients undergoing curative gastric cancer surgery. European Journal of Surgical Oncology, 40, 345-51.
  12. Qiao W, Wang T, Zhang L, et al (2013). Association study of single nucleotide polymorphisms in XRCC1 gene with the risk of gastric cancer in Chinese population. International Journal of Biological Sciences, 9, 753-8.
  13. Shim HJ, Yun JY, Hwang JE, et al (2010). BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Science, 101, 1247-54.
  14. Son T, Hyung WJ, Kim JW, et al (2014). Anatomic extent of metastatic lymph nodes: Still important for gastric cancer prognosis. Annals of Surgical Oncology, 21, 899-7.
  15. Suwanrungruang K, Wiangnon S, Sriamporn S, et al (2006). Trends in incidences of stomach and colorectal cancer in Khon Kaen, Thailand 1985-2004. Asian Pac J Cancer Prev, 7, 623-6.
  16. Tahara T, Shibata T, Nakamura M, et al (2011). Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients. Anticancer Research, 31, 705-10.
  17. Deng J, Zhang R, Pan Y, et al (2015). Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1,521 patients. Annals of Surgical Oncology, 22, 565-72.
  18. Deng J, Zhang R, Pan Y, et al (2014). N stages of the seventh edition of TNM Classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy. Tumor Biology, 35, 3269-81.
  19. Engin AB, Karahalil B, Karakaya A, Engin A (2011). Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arhiv Za Higijenu Rada I Toksikologiju, 62, 207-14.
  20. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-917.
  21. Herbreteau E, Jooste V, Hamza S, Lepage C, et al (2015). Trends in the management of gastric cancer over a 32-year period: a French population-based study. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 18, 129-37.
  22. Hong SH, Choi JK, Ahn DH, et al (2009).Association of the XRCC1 gene polymorphisms in patients with stomach cancer. Genes and Genomics, 31, 435-41.
  23. Kwon KJ, Shim KN, Song EM , et al (2014). Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer, 17, 43-53.
  24. Li F, Zhang R, Liang H, et al (2013). A retrospective clinicopathologic study of remnant gastric cancer after distal gastrectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 36, 244-9.
  25. Chen B, Zhou Y,Yang P, et al (2012). Polymorphisms of XRCC1 and gastric cancer susceptibility: A meta-analysis. Molecular Biology Reports, 39, 1305-13.
  26. Choi JY,Shim KN, Roh SH, et al (2011). [Clinicopathological characteristics of gastric cancer and survival improvement by surgical treatment in the elderly]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 58, 9-19.

Cited by

  1. Variant Alleles in XRCC1 Arg194Trp and Arg399Gln Polymorphisms Increase Risk of Gastrointestinal Cancer in Sabah, North Borneo vol.17, pp.4, 2016,
  2. -V109G Polymorphism Is Not Associated with the Risk of Prostate Cancer: A Case-Control Study of Han Chinese Men in Central China vol.2018, pp.1875-8630, 2018,